Glutathione reductase of the malarial parasite Plasmodium falciparum: Crystal structure and inhibitor development

Journal of Molecular Biology

Volumn 328, Issue 4, 2003, Pages 893-907

  Sarma, G N ^a   Savvides, S N ^a,d   Becker, K ^b   Schirmer, M ^b,c   Schirmer, R H ^c   Karplus, P A ^a  

^a OREGON STATE UNIVERSITY   (United States)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

10 arylisoalloxazines; Crystal structure; Drug design; Malaria; Plasmodium falciparum glutathione reductase

Indexed keywords

CHLOROQUINE; DIMER; FLAVOPROTEIN; GLUTATHIONE REDUCTASE; PEPTIDE DERIVATIVE; PROTEIN; PROTEIN INHIBITOR;

AMINO ACID SEQUENCE; ARTICLE; COMPARATIVE STUDY; COMPETITIVE INHIBITION; CRYSTAL STRUCTURE; DENSITY; DIMERIZATION; DISEASE PREDISPOSITION; DRUG DESIGN; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG TARGETING; ELECTRICITY; ENZYME ANALYSIS; ENZYME BINDING; ENZYME KINETICS; FUNCTIONAL ASSESSMENT; HUMAN; MUTANT; NONHUMAN; PLASMODIUM; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FOLDING; PROTEIN STRUCTURE;

INSERTION SEQUENCES; PLASMODIUM FALCIPARUM;

EID: 0037427472     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2836(03)00347-4     Document Type: Article

References (86)

1. Greenwood B., Mutabingwa T. Malaria in 2002. Nature. 415:2002;670-672.
2. Sachs J., Malaney P. The economic and social burden of malaria. Nature. 415:2002;680-685.
3. Miller L.H., Baruch D.I., Marsh K., Doumbo O.K. The pathogenic basis of malaria. Nature. 415:2002;673-679.
4. Olliaro P. Mode of action and mechanisms of resistance for antimalarial drugs. Pharmacol. Ther. 89:2001;207-219.
5. Hyde J.E. Mechanisms of resistance of Plasmodium falciparum to antimalarial drugs. Microbes Infect. 4:2002;165-174.
6. Ridley R.G. Medical need, scientific opportunity and the drive for antimalarial drugs. Nature. 415:2002;686-693.
7. Schirmer R.H., Müller J.G., Krauth-Siegel R.L. Disulfide-reductase inhibitors as chemotherapeutic agents: the design of drugs for typanosomiasis and malaria. Angew. Chem., Int. Ed. Engl. 34:1995;141-154.
8. Loria P., Miller S., Foley M., Tilley L. Inhibition of the peroxidative degradation of haem as the basis of action of chloroquine and other quinoline antimalarials. Biochem. J. 339:1999;363-370.
9. Foley M., Tilley L. Quinoline antimalarials: mechanisms of action and resistance and prospects for new agents. Pharmacol. Ther. 79:1998;55-87.
10. Ginsburg H., Famin O., Zhang J., Krugliak M. Inhibition of glutathione-dependent degradation of heme by chloroquine and amodiaquine as a possible basis for their antimalarial mode of action. Biochem. Pharmacol. 56:1998;1305-1313.
11. Egan T.J., Ross D.C., Adams P.A. Quinoline anti-malarial drugs inhibit spontaneous formation of beta-haematin (malaria pigment). FEBS Letters. 352:1994;54-57.
12. Zhang J., Krugliak M., Ginsburg H. The fate of ferriprotoporphyrin IX in malaria infected erythrocytes in conjunction with the mode of action of antimalarial drugs. Mol. Biochem. Parasitol. 99:1999;129-141.
13. Meshnick S.R., Taylor T.E., Kamchonwongpaisan S. Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. Microbiol. Rev. 60:1996;301-315.
14. Dubois V.L., Platel D.F., Pauly G., Tribouley-Duret J. Plasmodium berghei: implication of intracellular glutathione and its related enzyme in chloroquine resistance in vivo. Expt. Parasitol. 81:1995;117-124.
15. Famin O., Krugliak M., Ginsburg H. Kinetics of inhibition of glutathione-mediated degradation of ferriprotoporphyrin IX by antimalarial drugs. Biochem. Pharmacol. 58:1999;59-68.
16. Platel D.F., Mangou F., Tribouley-Duret J. Role of glutathione in the detoxification of ferriprotoporphyrin IX in chloroquine-resistant Plasmodium berghei. Mol. Biochem. Parasitol. 98:1999;215-223.
17. Austin S.E., Khan M.O., Douglas K.T. Rational drug design using trypanothione reductase as a target for anti-trypanosomal and anti-leishmanial drug leads. Drug Des. Discov. 16:1999;5-23.
18. Rahlfs S., Fischer M., Becker K. Plasmodium falciparum possesses a classical glutaredoxin and a second, glutaredoxin-like protein with a PICOT homology domain. J. Biol. Chem. 276:2001;37133-37140.
19. Iozef R., Becker K., Böhme C.C., Schirmer R.H., Werner D. Assembly and functional expression of murine glutathione reductase cDNA: a sequence missing in expressed sequence tag libraries. Biochim. Biophys. Acta. 1500:2000;137-141.
20. Schirmer R.H., Bauer H., Becker K. Glutathione reductase. Creighton T.E. Wiley Encyclopedia of Molecular Medicine. 2002;1471-1475 Wiley, New York.
21. Krauth-Siegel R.L., Müller J.G., Lottspeich F., Schirmer R.H. Glutathione reductase and glutamate dehydrogenase of Plasmodium falciparum, the causative agent of tropical malaria. Eur. J. Biochem. 235:1996;345-350.
22. Färber P.M., Becker K., Müller S., Schirmer R.H., Franklin R.M. Molecular cloning and characterization of a putative glutathione reductase gene, the PfGR2 gene, from Plasmodium falciparum. Eur. J. Biochem. 239:1996;655-661.
23. Färber P.M., Arscott L.D., Williams C.H. Jr, Becker K., Schirmer R.H. Recombinant Plasmodium falciparum glutathione reductase is inhibited by the antimalarial dye methylene blue. FEBS Letters. 422:1998;311-314.
24. Böhme C.C., Arscott L.D., Becker K., Schirmer R.H., Williams C.H. Jr. Kinetic characterization of glutathione reductase from the malarial parasite Plasmodium falciparum. Comparison with the human enzyme. J. Biol. Chem. 275:2000;37317-37323.
25. Gilberger T.W., Schirmer R.H., Walter R.D., Müller S. Deletion of the parasite-specific insertions and mutation of the catalytic triad in glutathione reductase from chloroquine-sensitive Plasmodium falciparum 3D7. Mol. Biochem. Parasitol. 107:2000;169-179.
26. Harwaldt P., Rahlfs S., Becker K. Glutathione S-transferase of the malarial parasite Plasmodium falciparum: characterization of a potential drug target. Biol. Chem. 383:2002;821-830.
27. Anderson B.B., Giuberti M., Perry G.M., Salsini G., Casadio I., Vullo C. Low red blood cell glutathione reductase and pyridoxine phosphate oxidase activities not related to dietary riboflavin: selection by malaria? Am. J. Clin. Nutr. 57:1993;666-672.
28. Atamna H., Pascarmona G., Ginsburg H. Hexose-monophosphate shunt activity in intact Plasmodium falciparum-infected erythrocytes and in free parasites. Mol. Biochem. Parasitol. 67:1994;79-89.
29. Cappadoro M., Giribaldi G., O'Brien E., Turrini F., Mannu F., Ulliers D., et al. Early phagocytosis of glucose-6-phosphate dehydrogenase (G6PD)-deficient erythrocytes parasitized by Plasmodium falciparum may explain malaria protection in G6PD deficiency. Blood. 92:1998;2527-2534.
30. Thurnham D.I., Oppenheimer S.J., Bull R. Riboflavin status and malaria in infants in Papua New Guinea. Trans. R. Soc. Trop. Med. Hyg. 77:1983;423-424.
31. Ruwende C., Hill A. Glucose-6-phosphate dehydrogenase deficiency and malaria. J. Mol. Med. 76:1998;581-588.
32. Beutler E., Luzzatto L. Hemolytic anemia. Semin. Hematol. 36:1999;38-47.
33. Ginsburg H., Golenser J. Redox metabolism in glucose-6-phosphate dehydrogenase deficient erythrocytes and its relation to antimalarial chemotherapy. Parassitologia. 41:1999;309-311.
34. Schirmer R.H., Krauth-Siegel R.L., Schulz G.E. Glutathione. Dolphin D., Poulsen R., Avramovic O. Coenzymes and Cofactors. 1989;553-596 Wiley, New York. Part A.
35. Zhang Y.A., Hempelmann E., Schirmer R.H. Glutathione reductase inhibitors as potential antimalarial drugs. Effects of nitrosoureas on Plasmodium falciparum in vitro. Biochem. Pharmacol. 37:1988;855-860.
36. Becker K., Schirmer R.H. 1,3-Bis(2-chloroethyl)-1-nitrosourea as thiol-carbamoylating agent in biological systems. Methods Enzymol. 251:1995;173-188.
37. Davioud-Charvet E., Delarue S., Biot C., Schwöbel B., Böhme C.C., Müssigbrodt A., et al. A prodrug form of a Plasmodium falciparum glutathione reductase inhibitor conjugated with a 4-anilinoquinoline. J. Med. Chem. 44:2001;4268-4276.
38. Becker K., Schirmer M., Kanzok S., Schirmer R.H. Flavins and flavoenzymes in diagnosis and therapy. Methods Mol. Biol. 131:1999;229-245.
39. Krauth-Siegel R.L., Coombs G.H. Enzymes of parasite thiol metabolism as drug targets. Parasitol. Today. 15:1999;404-409.
40. Ginsburg H. A double-headed pro-drug that overcomes chloroquine resistance. Trends Parasitol. 18:2002;103.
41. Anstey N.M., Hassanali M.Y., Mlalasi J., Manyenga D., Mwaikambo E.D. Elevated levels of methaemoglobin in Tanzanian children with severe and uncomplicated malaria. Trans. R. Soc. Trop. Med. Hyg. 90:1996;147-151.
42. Pai E.F., Karplus P.A., Schulz G.E. Crystallographic analysis of the binding of NADPH, NADPH fragments, and NADPH analogues to glutathione reductase. Biochemistry. 27:1988;4465-4474.
43. Karplus P.A., Schulz G.E. Refined structure of glutathione reductase at 1.54 Å resolution. J. Mol. Biol. 195:1987;701-729.
44. Keese M.A., Böse M., Mülsch A., Schirmer R.H., Becker K. Dinitrosyl-dithiol-iron complexes, nitric oxide (NO) carriers in vivo, as potent inhibitors of human glutathione reductase and glutathione-S-transferase. Biochem. Pharmacol. 54:1997;1307-1313.
45. Becker K., Savvides S.N., Keese M., Schirmer R.H., Karplus P.A. Enzyme inactivation through sulfhydryl oxidation by physiologic NO-carriers. Nature Struct. Biol. 5:1998;267-271.
46. Savvides S.N., Scheiwein M., Böhme C.C., Arteel G.E., Karplus P.A., Becker K., Schirmer R.H. Crystal structure of the antioxidant enzyme glutathione reductase inactivated by peroxynitrite. J. Biol. Chem. 277:2002;2779-2784.
47. Karplus P.A., Schulz G.E. Substrate binding and catalysis by glutathione reductase as derived from refined enzyme:substrate crystal structures at 2 Å resolution. J. Mol. Biol. 210:1989;163-180.
48. Karplus P.A., Pai E.F., Schulz G.E. A crystallographic study of the glutathione binding site of glutathione reductase at 0.3-nm resolution. Eur. J. Biochem. 178:1989;693-703.
49. Savvides S.N., Karplus P.A. Kinetics and crystallographic analysis of human glutathione reductase in complex with a xanthene inhibitor. J. Biol. Chem. 271:1996;8101-8107.
50. Schönleben-Janas A., Kirsch P., Mittl P.R., Schirmer R.H., Krauth-Siegel R.L. Inhibition of human glutathione reductase by 10-arylisoalloxazines: crystalline, kinetic, and electrochemical studies. J. Med. Chem. 39:1996;1549-1554.
51. Becker K., Christopherson R.I., Cowden W.B., Hunt N.H., Schirmer R.H. Flavin analogs with antimalarial activity as glutathione reductase inhibitors. Biochem. Pharmacol. 39:1990;59-65.
52. Luond R.M., McKie J.H., Douglas K.T., Dascombe M.J., Vale J. Inhibitors of glutathione reductase as potential antimalarial drugs. Kinetic cooperativity and effect of dimethyl sulphoxide on inhibition kinetics. J. Enzyme Inhib. 13:1998;327-345.
53. Schirmer, M. (2000). Ein Doppelhelix-Motiv als Zielstruktur des Drug Design: Die Interface-Domäne obligat dimerer Disulfidreduktasen. MD thesis, Heidelberg University.
54. Nordhoff A., Tziatzios C., van den Broek J.A., Schott M.K., Kalbitzer H.R., Becker K., et al. Denaturation and reactivation of dimeric human glutathione reductase. An assay for folding inhibitors. Eur. J. Biochem. 245:1997;273-282.
55. Nordhoff A., Bücheler U.S., Werner D., Schirmer R.H. Folding of the four domains and dimerization are impaired by the Gly446Glu exchange in human glutathione reductase. Implications for the design of antiparasitic drugs. Biochemistry. 32:1993;4060-4066.
56. Luzzati V. Traitement statistique des erreurs dans la determination des structures cristallines. Acta Crystallog. 5:1952;802-810.
57. Kleywegt G.J., Brunger A.T. Checking your imagination: applications of the free R value. Structure. 4:1996;897-904.
58. Winn M.D., Isupov M.N., Murshudov G.N. Use of TLS parameters to model anisotropic displacements in macromolecular refinement. Acta Crystallog. sect. D. Biol. Crystallog. 57:2001;122-133.
59. Murshudov G.N., Vagin A.A., Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallog. sect. D. Biol. Crystallog. 53:1997;240-255.
60. Kleywegt G.J., Jones T.A. Phi/psi-chology: Ramachandran revisited. Structure. 4:1996;1395-1400.
61. Janes W., Schulz G.E. Role of the charged groups of glutathione disulfide in the catalysis of glutathione reductase: crystallographic and kinetic studies with synthetic analogues. Biochemistry. 29:1990;4022-4030.
62. Vennerstrom J.L., Makler M.T., Angerhofer C.K., Williams J.A. Antimalarial dyes revisited: xanthenes, azines, oxazines, and thiazines. Antimicrob. Agents Chemother. 39:1995;2671-2677.
63. Kirsch P., Schönleben-Janas A., Schirmer R.H. Synthesis and characterization of water-soluble and photolabile 10-arylisoalloxazines: tools for studying the mechanism of flavin-type antimalarials. Liebigs Ann. 1995:1995;1275-1281.
64. Antonov L., Gergov G., Petrov V., Kubista M., Nygren J. UV-Vis spectroscopic and chemometric study on the aggregation of ionic dyes in water. Talanta. 49:1999;99-106.
65. Bhatia A., Charet P. Action of chloroquine on glutathione metabolism in erythrocytes parasitized by Plasmodium berghei. Ann. Parasitol. Hum. Comp. 59:1984;317-320.
66. Brunger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., et al. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallog. sect. D. Biol. Crystallog. 54:1998;905-921.
67. Jones T.A., Zou J.Y., Cowan S.W., Kjeldgaard M. Improved methods for binding protein models in electron density maps and the location of errors in these models. Acta Crystallog. sect. A. 47:1991;110-119.
68. The CCP4 suite: programs for protein crystallography. Acta Crystallog. sect. D., Biol. Crystallog. 50:1994;760-763.
69. Laskowski R.A., MacArthur M.W., Moss D.S., Thornton J.M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallog. 26:1993;283-291.
70. Howlin B., Butler S.A., Moss D.S., Harris G.W., Driessen H.P.C. TLSANL: TLS parameter-analysis program for segmented anisotropic refinement of macromolecular structures. J. Appl. Crystallog. 26:1993;622-624.
71. Kabsch W., Sander C. Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers. 22:1983;2577-2637.
72. Bruns C.M., Hubatsch I., Ridderstrom M., Mannervik B., Tainer J.A. Human glutathione transferase A4-4 crystal structures and mutagenesis reveal the basis of high catalytic efficiency with toxic lipid peroxidation products. J. Mol. Biol. 288:1999;427-439.
73. Mittl P.R., Schulz G.E. Structure of glutathione reductase from Escherichia coli at 1.86 Å resolution: comparison with the enzyme from human erythrocytes. Protein Sci. 3:1994;799-809.
74. Kleywegt G.J., Jones T.A. Detection, delineation, measurement and display of cavities in macromolecular structures. Acta Crystallog. sect. D. Biol. Crystallog. 50:1994;178-185.
75. Nicholls A., Sharp K.A., Honig B. Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins: Struct. Funct. Genet. 11:1991;281-296.
76. Bondi A. van der Waals volumes and radii. J. Phys. Chem. 68:1964;441-451.
77. Kraulis P.J. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallog. 24:1991;946-950.
78. Merritt E.A., Bacon D.J. Raster3D: photorealistic molecular graphics. Methods Enzymol. 277:1997;505-524.
79. Gromer S., Merkle H., Schirmer R.H., Becker K. Human placenta thioredoxin reductase: preparation and inhibitor studies. Methods Enzymol. 347:2002;382-394.
80. Trager W., Jensen J.B. Human malaria parasites in continuous culture. Science. 193:1976;673-675.
81. Lambros C., Vanderberg J.P. Synchronization of Plasmodium falciparum erythrocytic stages in culture. J. Parasitol. 65:1979;418-420.
82. Hodel A., Kim S.-H., Brunger A.T. Model bias in macromolecular crystal structures. Acta Crystallog. sect. A. 48:1992;851-858.
83. Becker, K. (1988). Glutathionreduktase und ihr Apoenzym: Beiträge zur Chemotherapie der Malaria und zur Diagnostik von FAD-Mangelzuständen. MD thesis, Heidelberg University.
84. Diederichs K., Karplus P.A. Improved R-factors for diffraction data analysis in macromolecular crystallography. Nature Struct. Biol. 4:1997;269-275.
85. Brunger A.T. Free R value: a novel statistical quantity for assessing the accuracy of crystal structures. Nature. 355:1992;472-475.
86. Thieme R., Pai E.F., Schirmer R.H., Schulz G.E. Three-dimensional structure of glutathione reductase at 2 Å resolution. J. Mol. Biol. 152:1981;763-782.